Axonis Therapeutics

Biotech · US

US biotech developing oral KCC2-targeting neuromedicines for epilepsy and pain.

Founders

Joanna Stanicka (Ireland · ♀) — A Harvard-trained UCC scientist and drug hunter who co-invented Axonis' KCC2-targeting IP and co-founded the company in 2020, leading it as CEO to develop neuromedicines for epilepsy and pain.
Shane Hegarty (Ireland · ♂) — A UCC and Harvard neuroscientist whose award-winning neuro-regeneration research at Boston Children's Hospital became the IP behind Axonis, which he co-founded as Chief Scientific Officer.

Date	Round	Amount
Oct 2024	Series A Axonis Therapeutics raised $115m in Series A financing co-led by Cormorant Asset Management and venBio Partners to advance its lead neuromedicine candidate AXN-027.	$115M
Jul 2021	Seed Axonis Therapeutics, co-founded by UCC graduates and based in Cambridge, Massachusetts, raised $5m led by Alexandria Venture Investments to develop therapies for neurological disorders.	$5M

Tap an investor to see what else they have backed.

Data is community-curated and may be incomplete.